



DIRECTOR NOT STANDING FOR RE-ELECTION AT AGM

29 October 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) advises that non-executive director Mr Phil Hodges will not be standing for re-election as a Director of the Company at the upcoming Annual General Meeting, to be held on 29 November 2018.

In accordance with the Company's constitution, Mr Hodges will retire as a Director effective at the Annual General Meeting. Mr Hodges joined the Mayne Pharma Board in November 2012 following the acquisition of Metrics, Inc. which he founded and has also served on the Company's Science, Technology and Medical Committee.

Mayne Pharma Chairman, Mr Roger Corbett said, "On behalf of the Board, I thank Phil for his vision, dedicated service and contribution to Mayne Pharma. Our Company has benefited greatly from Phil's entrepreneurship and the Metrics, Inc acquisition which provided Mayne Pharma with an operating platform in the worlds' largest pharmaceutical market. Over the last six years, Mayne Pharma has doubled the contract service business from US\$24m to US\$49m in sales and the generic business has grown from US\$28m to US\$299m in sales driven by new product launches, strategic acquisitions and an array of commercial initiatives. We are very grateful to Phil for his significant contributions to Mayne Pharma's success and we wish him well for the future."

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including potent compounds, controlled substances, modified release products and inherently unstable compounds.